TABLE A-2
CLINICAL CHEMISTRY AND IMMUNOLOGY
|
ANALYTE |
SPECIMENa |
SI UNITS |
CONVENTIONAL UNITS |
|
2-3 weeks postconception |
75-2600IU/L |
75-2600 mIU/mL |
|
|
3-4 weeks postconception |
850-20,800 IU/L |
850-20,800 mIU/mL |
|
|
4-5 weeks postconception |
4000-100,200 IU/L |
4000-100,200 mIU/mL |
|
|
5-10 weeks postconception |
11,500-289,000 IU/L |
11,500-289,000 mIU/mL |
|
|
10-14 weeks postconception |
18,300-137,000 IU/L |
18,300-137,000 mIU/mL |
|
|
Second trimester |
1400-53,000 IU/L |
1400-53,000 mIU/mL |
|
|
Third trimester |
940-60,000 IU/L |
940-60,000 mIU/mL |
|
|
ß-Hydroxybutyrate |
P |
0-290 μ^^^ |
0-3 mg/dL |
|
5-Hydroindoleacetic acid (5-HIAA) |
U |
10.5-36.6 μ^^^ |
2-7 mg/d |
|
17-Hydroxyprogesterone (adult) |
S |
||
|
Male |
0.15-7.5 nmol/L |
5-250 ng/dL |
|
|
Female |
|||
|
Follicular phase |
0.6-3.0 nmol/L |
20-100 ng/dL |
|
|
Midcycle peak |
3-7.5 nmol/L |
100-250 ng/dL |
|
|
Luteal phase |
3-15 nmol/L |
100-500 ng/dL |
|
|
Postmenopausal |
< 2.1 nmol/L |
< 70 ng/dL |
|
|
Hydroxyproline |
U, 24 hour |
38-500 μ^^^ |
38-500 μ^^^ |
|
Immunofixation |
S |
Not applicable |
No bands detected |
|
Immunoglobulin, quantitation (adult) |
|||
|
IgA |
S |
0.70-3.50 g/L |
70-350 mg/dL |
|
IgD |
S |
0-140 mg/L |
0-14 mg/dL |
|
IgE |
S |
24-430 μg/L |
10-179 IU/mL |
|
IgG |
S |
7.0-17.0 g/L |
700-1700 mg/dL |
|
IgG1 |
S |
2.7-17.4 g/L |
270-1740 mg/dL |
|
IgG2 |
S |
0.3-6.3 g/L |
30-630 mg/dL |
|
IgG3 |
S |
0.13-3.2 g/L |
13-320 mg/dL |
|
IgG4 |
S |
0.11-6.2 g/L |
11-620 mg/dL |
|
IgM |
S |
0.50-3.0 g/L |
50-300 mg/dL |
|
Insulin |
S, P |
14.35-143.5 pmol/L |
2-20 μ^ιτ^ |
|
Iron |
S |
7-25 μ^^^ |
41-141 μg/dL |
|
Iron-binding capacity |
S |
45-73 μ^^^ |
251-406 μg/dL |
|
Iron-binding capacity saturation |
S |
0.16-0.35 |
16-35% |
|
Joint fluid crystal |
JF |
Not applicable |
No crystals seen |
|
Joint fluid mucin |
JF |
Not applicable |
Only type I mucin present |
|
Ketone (acetone) |
S, U |
Negative |
Negative |
|
17 Ketosteroids |
U |
0.003-0.012 g/d |
3-12 mg/d |
|
Lactate |
P, arterial |
0.5-1.6 mmol/L |
4.5-14.4 mg/dL |
|
P, venous |
0.5-2.2 mmol/L |
4.5-19.8 mg/dL |
|
|
Lactate dehydrogenase |
S |
2.0-3.8 μkat/L |
115-221 U/L |
|
Lactate dehydrogenase isoenzymes |
S |
||
|
Fraction 1 (of total) |
0.14-0.26 |
14-26% |
|
|
Fraction 2 |
0.29-0.39 |
29-39% |
|
|
Fraction 3 |
0.20-0.25 |
20-25% |
|
|
Fraction 4 |
0.08-0.16 |
8-16% |
|
|
Fraction 5 |
0.06-0.16 |
6-16% |
|
|
Lipase (method dependent) |
S |
0.51-0.73 μkat/L |
3-43 U/L |
|
Lipids: see Table A-5 |
|||
|
Lipoprotein (a) |
S |
0-300 mg/L |
0-30 mg/dL |
|
Low-density lipoprotein (LDL) (see Table A-5) |
|||
|
Luteinizing hormone (LH) |
S, P |
||
|
Female |
|||
|
Menstruating: |
|||
|
Follicular phase |
2.0-15.0 U/L |
2.0-15.0 U/L |
|
|
Ovulatory phase |
22.0-105.0 U/L |
22.0-105.0 U/L |
|
|
Luteal phase |
0.6-19.0 U/L |
0.6-19.0 U/L |
|
|
Postmenopausal |
16.0-64.0 U/L |
16.0-64.0 U/L |
|
|
Male |
2.0-12.0 U/L |
2.0-12.0 U/L |
TABLE A-2
CLINICAL CHEMISTRY AND IMMUNOLOGY
|
ANALYTE |
SPECIMENa |
SI UNITS |
CONVENTIONAL UNITS |
|
Magnesium |
S |
0.62-0.95 mmol/L |
1.5-2.3 mg/dL |
|
Metanephrine |
P |
<0.5 nmol/L |
<100 pg/mL |
|
Metanephrine |
U |
30-211 mmol/mol creatinine |
53-367 μg/g creatinine |
|
Methemoglobin |
WB |
0.0-0.01 |
0-1% |
|
Microalbumin urine |
U |
||
|
24-h urine |
0.0-0.03 g/d |
0-30 mg/24 h |
|
|
Spot urine |
0.0-0.03 g/g creatinine |
0-30 μg/mg creatinine |
|
|
Myoglobin |
S |
||
|
Male |
19-92 μg/L |
19-92 μg/L |
|
|
Female |
12-76 μg/L |
12-76 μg/L |
|
|
Norepinephrine |
U |
89-473 nmol/d |
15-80 μg/d |
|
Norepinephrine |
P |
||
|
Supine (30 min) |
650-2423 pmol/L |
110-410 pg/mL |
|
|
Sitting |
709-4019 pmol/L |
120-680 pg/mL |
|
|
Standing (30 min) |
739-4137 pmol/L |
125-700 pg/mL |
|
|
N-telopeptide (cross linked), NTx |
S |
||
|
Female, premenopausal |
6.2-19.0 nmol BCE |
6.2-19.0 nmol BCE |
|
|
Male |
5.4-24.2 nmol BCE |
5.4-24.2 nmol BCE |
|
|
Bone collagen equivalent (BCE) |
|||
|
N-telopeptide (cross linked), NTx |
U |
||
|
Female, premenopausal |
17-94 nmol BCE/mmol creatinine |
17-94 nmol BCE/mmol creatinine |
|
|
Female, postmenopausal |
26-124 nmol BCE/mmol creatinine |
26-124 nmol BCE/mmol creatinine |
|
|
Male |
21-83 nmol BCE/mmol |
21-83 nmol BCE/mmol |
|
|
creatinine |
creatinine |
||
|
Bone collagen equivalent (BCE) |
|||
|
5′ Nucleotidase |
S |
0.02-0.19 μkat/L |
0-11 U/L |
|
Osmolality |
P |
275-295 mosmol/kg serum water |
275-295 mosmol/kg serum water |
|
U |
500-800 mosmol/kg |
500-800 mosmol/kg |
|
|
water |
water |
||
|
Osteocalcin |
S |
11-50 μg/L |
11-50 ng/mL |
|
Oxygen content |
WB |
||
|
Arterial (sea level) |
17-21 |
17-21 vol% |
|
|
Venous (sea level) |
10-16 |
10-16 vol% |
|
|
Oxygen percent saturation (sea level) |
WB |
||
|
Arterial |
0.97 |
94-100% |
|
|
Venous, arm |
0.60-0.85 |
60-85% |
|
|
Parathyroid hormone (intact) |
S |
8-51 ng/L |
8-51 pg/mL |
|
Phosphatase, alkaline |
S |
0.56-1.63 μkat/L |
33-96 U/L |
|
Phosphorus, inorganic |
S |
0.81-1.4 mmol/L |
2.5-4.3 mg/dL |
|
Porphobilinogen |
U |
None |
None |
|
Potassium |
S |
3.5-5.0 mmol/L |
3.5-5.0 meq/L |
|
Prealbumin |
S |
170-340 mg/L |
17-34 mg/dL |
|
Progesterone |
S, P |
||
|
Female |
|||
|
Follicular |
<3.18 nmol/L |
<1.0 ng/mL |
|
|
Midluteal |
9.54-63.6 nmol/L |
3-20 ng/mL |
|
|
Male |
<3.18 nmol/L |
<1.0 ng/mL |
|
|
Prolactin |
S |
0-20 μg/L |
0-20 ng/mL |
|
Prostate-specific antigen (PSA) |
S |
||
|
Male |
|||
|
<40 years |
0.0-2.0 μg/L |
0.0-2.0 ng/mL |
|
|
>40 years |
0.0-4.0 μg/L |
0.0-4.0 ng/mL |
TABLE A-2
CLINICAL CHEMISTRY AND IMMUNOLOGY
|
ANALYTE |
SPECIMENa |
SI UNITS |
CONVENTIONAL UNITS |
|
PSA, free; in males 45-75 years, with |
S |
>0.25 associated with |
>25% associated with |
|
PSA values between 4 and 20 μg/mL |
benign prostatic hyperplasia |
benign prostatic hyperplasia |
|
|
Protein fractions |
S |
||
|
Albumin |
35-55 g/L |
3.5-5.5 g/dL (50-60%) |
|
|
Globulin |
20-35 g/L |
2.0-3.5 g/dL (40-50%) |
|
|
Alpha1 |
2-4 g/L |
0.2-0.4 g/dL (4.2-7.2% |
|
|
Alpha2 |
5-9 g/L |
0.5-0.9 g/dL (6.8-12% |
|
|
Beta |
6-11 g/L |
0.6-1.1 g/dL (9.3-15% |
|
|
Gamma |
7-17 g/L |
0.7-1.7 g/dL (13-23%) |
|
|
Protein, total |
S |
67-86 g/L |
6.7-8.6 g/dL |
|
Pyruvate |
P, arterial |
40-130 μmol/L |
0.35-1.14 mg/dL |
|
P, venous |
40-130 μmol/L |
0.35-1.14 mg/dL |
|
|
Rheumatoid factor |
S, JF |
<30 kIU/L |
<30 IU/mL |
|
Serotonin |
WB |
0.28-1.14 μ(^^ |
50-200 ng/mL |
|
Serum protein electrophoresis |
S |
Not applicable |
Normal pattern |
|
Sex hormone binding globulin (adult) |
S |
||
|
Male |
13-71 nmol/L |
13-71 nmol/L |
|
|
Female |
18-114 nmol/L |
18-114 nmol/L |
|
|
Sodium |
S |
136-146 mmol/L |
136-146 meq/L |
|
Somatomedin-C (IGF-1) (adult) |
S |
||
|
16-24 years |
182-780 μg/L |
182-780 ng/mL |
|
|
25-39 years |
114-492 μg/L |
114-492 ng/mL |
|
|
40-54 years |
90-360 μg/L |
90-360 ng/mL |
|
|
>54 years |
71-290 μg/L |
71-290 ng/mL |
|
|
Somatostatin |
P |
<25 ng/L |
<25 pg/mL |
|
Testosterone, total, morning sample |
S |
||
|
Female |
0.21-2.98 nmol/L |
6-86 ng/dL |
|
|
Male |
9.36-37.10 nmol/L |
270-1070 ng/dL |
|
|
Thyroglobulin |
S |
0.5-53 μg/L |
0.5-53 ng/mL |
|
Thyroid-binding globulin |
S |
13-30 mg/L |
1.3-3.0 mg/dL |
|
Thyroid-stimulating hormone |
S |
0.34-4.25 mIU/L |
0.34-4.25 ^U/mL |
|
Thyroxine, free (fT4) |
S |
10.3-21.9 pmol/L |
0.8-1.7 ng/dL |
|
Thyroxine, total (T4) |
S |
70-151 nmol/L |
5.4-11.7 μg/dL |
|
(Free) thyroxine index |
S |
6.7-10.9 |
6.7-10.9 |
|
Transferrin |
S |
2.0-4.0 g/L |
200-400 mg/dL |
|
Triglycerides (see Table A-5) |
S |
0.34-2.26 mmol/L |
30-200 mg/dL |
|
Triiodothyronine, free (fT3) |
S |
3.7-6.5 pmol/L |
2.4-4.2 pg/mL |
|
Triiodothyronine, total (T3) |
S |
1.2-2.1 nmol/L |
77-135 ng/dL |
|
Troponin I |
S |
||
|
Normal population, 99 %tile |
0-0.08 μg/L |
0-0.08 ng/mL |
|
|
Cut-off for MI |
>0.4 μg/L |
>0.4 ng/mL |
|
|
Troponin T |
S |
||
|
Normal population, 99 %tile |
0-0.1 μg/L |
0-0.01 ng/mL |
|
|
Cut-off for MI |
0-0.1 μg/L |
0-0.1 ng/mL |
|
|
Urea nitrogen |
S |
2.5-7.1 mmol/L |
7-20 mg/dL |
|
Uric acid |
S |
||
|
Females |
0.15-0.33 μmol/L |
2.5-5.6 mg/dL |
|
|
Males |
0.18-0.41 μmol/L |
3.1-7.0 mg/dL |
|
|
Urobilinogen |
U |
0.09-4.2 μmol/d |
0.05-25 mg/24 h |
|
Vanillylmandelic acid (VMA) |
U, 24h |
<30 μmol/d |
<6 mg/d |
|
Vasoactive intestinal polypeptide |
P |
0-60 ng/L |
0-60 pg/mL |
aP, plasma; S, serum; U, urine; WB, whole blood; JF, joint fluid.
